Saying Yes to Life and to Lasting Pain Relief

That’s the living proof of the Intracept Procedure: The only targeted way to relieve vertebrogenic chronic low back pain (CLBP). Here’s the basics:

A Certain Nerve Is the Key

Vertebral endplates – found on either side of the disc – can become damaged over time, causing inflammation and back pain. The basivertebral nerve (BVN), found within the vertebrae, carries these back pain signals from the inflamed endplates to the brain.

Treating BVN

The Intracept Procedure Can Relieve the Pain

The Intracept Procedure is a same-day procedure performed in an outpatient surgery center. Unlike some major surgeries, the Intracept Procedure is implant-free and preserves the overall structure of the spine.

The Intracept Procedure involves heating the basivertebral nerve with a radiofrequency probe to stop it from sending pain signals to the brain. Patients are under anesthesia, and the procedure generally lasts an hour.

Different from other nerves in the body that regenerate, the BVN has not shown an ability to grow back as a pain-transmitting nerve following the Intracept Procedure.

What to Expect After the Procedure

Following the procedure, the doctor may recommend some precautions to take – and after a brief recovery period, most people resume normal activities.

Lasting Pain Relief

Most people start to feel pain relief within two weeks after the Intracept Procedure. And what separates the Intracept Procedure from other radiofrequency ablation procedures is its long-term relief after a single procedure.

Patients in a recent study reported their improvements in function and pain relief lasted more than 5 years following the procedure – with over a third of these patients indicating they were totally pain-free.1

Take the Next Step

Find a Doctor

In a few steps, see if you may benefit from the procedure, and connect with an Intracept-trained physician near you.

ZIP Code

Join the Intracept Physician Community

Add the Intracept Procedure to your practice, gaining the clinical support, peer expertise, and program development resources needed to bring Living Proof to your patients.

As with any surgical procedure, there are risks and considerations associated with the Intracept Procedure. See important safety information below.

Physicians: See Indications, Contraindications, and Risks

The Intracept Procedure Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI such as inflammation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change).

Use of the Intracept Procedure Intraosseous Nerve Ablation System is contraindicated in:

  • Patients with severe cardiac or pulmonary compromise
  • Patients where the targeted ablation zone is < 10 mm away from a sensitive structure not intended to be ablated, including the vertebral foramen (spinal canal)
  • Patients with active systemic infection or local infection in the area to be treated
  • Patients who are pregnant
  • Skeletally immature patients (generally < 18 years of age)
  • Patients with active implantable pulse generators (e.g., pacemakers, defibrillators)
  • Situations where unintended tissue damage may result, based on the clinical assessment by the physician
  • Application with electrosurgical instruments NOT tested and specified for use with the Relievant RFG
Patients: See the Indications & Risks Involved
  • The Intracept Access Instruments and the Intracept RF Probe are single patient use only. The Introducer Cannula, Diamond Stylet, Bevel Stylet, J-Stylet, Straight Stylet, Drill, and Probe may be used to treat up to a maximum of four (4) vertebrae (L3, L4, L5, S1) on a single patient, while the Curved Cannula may only be used on one (1) vertebra on a single patient.
  • As with any surgical instrument, careful attention must be exercised to ensure that excessive force is not placed on the Instruments or Probe. Excessive force can result in product failure.
  • Prior to the procedure, CT or MRI imaging must be utilized to help define the desired treatment site and define working anatomical landmarks that can be used for mapping access to the treatment site.
  • The device should be manipulated only while under fluoroscopic or CT observation.
  • DO NOT use this device in the presence of flammable anesthetics, other flammable gases or objects, near flammable fluids such as skin prepping agents and tinctures, or oxidizing agents. Observe appropriate fire precautions at all times. There is a risk of pooling of flammable solutions under the patient or in body depressions and cavities.
  • Fluids pooled in the body depressions and cavities of the patient should be mopped up before RFG is used.
  • There is a danger of ignition of endogenous gases (e.g., cotton and gauze saturated with oxygen may be ignited by sparks produced during normal use of the RFG).
  • Operator may choose to use smoke-plume extraction apparatus, though the indicated procedure is unlikely to produce noticeable smoke
  • The Probe is for use WITHOUT a neutral electrode (ie., a grounding pad).
  • Discontinue use if inaccurate, erratic or sluggish temperature readings are observed. Use of damaged equipment may cause patient injury.
  • Prior to operation, visually inspect the Probe and RF for physical damage, obvious cracks in insulation or loose parts.
  • During power delivery, the cable should not come in direct contact with the patient's skin or other patient leads.
  • Safety and effectiveness in patients with conditions that are associated with poor bone quality such as osteoporosis have not been established.

CONTRAINDICATIONS

Use of the Intracept Intraosseous Nerve Ablation System is contraindicated in:

  • Patients with severe cardiac or pulmonary compromise
  • Patients with active implantable pulse generators (e.g. pacemakers, defibrillators)
  • Patients where the targeted ablation zone is < 10 mm away from a sensitive structure not intended to be ablated, including the vertebral foramen (spinal canal)
  • Patients with active systemic infection or local infection in the area to be treated
  • Patients who are pregnant
  • Skeletally immature patients (generally ≤ 18 years of age)

WARNINGS

  • Do not use if package is opened or damaged as product integrity and/or sterility may be compromised.
  • Do not use after the expiration date has passed as product integrity and/or sterility may be compromised.
  • Do not re-sterilize or reuse. Re-sterilization or reuse may result in cross contamination, patient infection, or device malfunction.
  • Reconditioning, refurbishing, repair or modification of the device to enable further use is prohibited.
  • Do not use this product if you have not been properly trained in its use. Physicians using the device should be familiar with the physiology and pathology of the selected anatomy to be treated and be trained in the performance of the chosen surgical technique. Improper surgical use and technique may lead to suboptimal clinical outcomes.
  • Read and understand the Instructions For Use ("IFU*) completely prior to use.
  • The Intracept System must be used with the Relievant Medsystems RF Generator in order to provide the required treatment parameters.
  • Failure of the RFG could result in an unintended increase of output power to the Probe.
  • The Intracept RF Probe may interfere and adversely influence the operation of other electronic equipment.
  1. Fischgrund J, Rhyne A, Macadaeg K, et al. Long-term outcomes following intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 5-year treatment arm results from a prospective randomized double-blind sham-controlled multi-center study. Eur Spine J. 2020;29(8):1925-34. http://doi.org/10.1007/s00586-020-06448-x